The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 741-744

  Jick, Susan S ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston Collab Drug Survlnc Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MELOXICAM; NAPROXEN; PIROXICAM;

ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; RISK ASSESSMENT;

EID: 0033919207     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.741.35209     Document Type: Article

References (4)

1. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998;37:937-45.
2. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (cox)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (select) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
3. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
4. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:347-9.